iPS Cells for Modelling and Treatment of Human Diseases by Michael J. EdeliPS Cells for Modelling and Treatment of Human Diseases by Michael J. Edel

iPS Cells for Modelling and Treatment of Human Diseases

Guest editorMichael J. Edel

Hardcover | November 16, 2015

Pricing and Purchase Info


Earn 699 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


The field of reprogramming somatic cells into induced pluripotent stem cells (iPSC) has moved very quickly, from bench to bedside in just eight years since its first discovery. The best example of this is the RIKEN clinical trial this year in Japan, which will use iPSC derived retinal pigmented epithelial (RPE) cells to treat macular degeneration (MD). This is the first human disease to be tested for regeneration and repair by iPSC-derived cells and others will follow in the near future. Currently, there is an intense worldwide research effort to bring stem cell technology to the clinic for application to treat human diseases and pathologies. Human tissue diseases (including those of the lung, heart, brain, spinal cord, and muscles) drive organ bioengineering to the forefront of technology concerning cell replacement therapy. Given the critical mass of research and translational work being performed, iPSCs may very well be the cell type of choice for regenerative medicine in the future. Also, basic science questions, such as efficient differentiation protocols to the correct cell type for regenerating human tissues, the immune response of iPSC replacement therapy and genetic stability of iPSC-derived cells, are currently being investigated for future clinical applications.

Title:iPS Cells for Modelling and Treatment of Human DiseasesFormat:HardcoverProduct dimensions:422 pages, 9.61 × 6.69 × 1.31 inShipping dimensions:9.61 × 6.69 × 1.31 inPublished:November 16, 2015Publisher:MDPI AGLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3038421227

ISBN - 13:9783038421221


Table of Contents

Chapter 1: NeuronalRoger Torrent, Francesca de Angelis Rigotti, Patrizia Dell'Era, Maurizio Memo, Angel Raya and Antonella ConsiglioUsing iPS Cells toward the Understanding of Parkinson's DiseaseDmitry A. Ovchinnikov and Ernst J. WolvetangOpportunities and Limitations of Modelling Alzheimer's Disease with Induced Pluripotent Stem CellsKristine Freude, Carlota Pires, Poul Hyttel and Vanessa Jane HallInduced Pluripotent Stem Cells Derived from Alzheimer's Disease Patients: The Promise, the Hope and the Path AheadIrene Faravelli, Emanuele Frattini, Agnese Ramirez, Giulia Stuppia, Monica Nizzardo and Stefania CortiiPSC-based Models to Unravel Key Pathogenetic Processes underlying Motor NeuronDiseases DevelopmentChapter 2: CardiacAlexis Bosman, Michael J. Edel, Gillian Blue, Rodney J. Dilley, Richard P. Harvey and David S. WinlawBioengineering and Stem Cell Technology in the Treatment of Congenital Heart DiseaseStephanie Friedrichs, Daniela Malan, Yvonne Voss and Philipp SasseScalable Electrophysiological Investigation of iPS Cell Derived Cardiomyocytes Obtained by a Lentiviral Purification StrategyKwong-Man Ng, Cheuk-Yiu Law and Hung-Fat TseClinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem CellsChapter 3: EyeFred Kuanfu Chen, Samuel McLenachan, Michael Edel, Lyndon Da Cruz, Peter Coffey and David A. MackeyiPS Cells for Modelling and Treatment of Retinal DiseasesHuy V. Nguyen, Yao Li and Stephen H. TsangPatient-Specific iPSC-Derived RPE for Modeling of Retinal DiseasesRicardo P. Casaroli-Marano, Núria Nieto-Nicolau, Eva M. Martínez-Conesa, Michael Edel and Ana B. Álvarez-PalomoPotential role of Induced Pluripotent Stem Cells (IPSCs) for Cell-Based Therapy of the Ocular SurfaceChapter 4: Spinal Cord InjuryMohamad Khazaei, Ahad M. Siddiqui and Michael G. FehlingsThe Potential for iPS-Derived Stem Cells as a Therapeutic Strategy for Spinal Cord Injury: Opportunities and ChallengesStuart I. Hodgetts, Michael J. Edel and Alan R. HarveyThe State of Play with iPSCs and Spinal Cord Injury ModelsChapter 5: LiverYue Yu, Xuehao Wang and Scott NybergPotential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases TreatmentChapter 6: MuscleIsart Roca, Jordi Requena, Michael J. Edel and Ana Belén Alvarez-PalomoMyogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement TherapyChapter 7: BoneI-Ping ChenThe Use of Patient-Specific Induced Pluripotent Stem Cells (iPSCs) to Identify Osteoclast Defects in Rare Genetic Bone DisordersChapter 8: Germ CellsTetsuya IshiiHuman iPS Cell-derived Germ Cells: Current Status and Clinical PotentialChapter 9: Genetic DisordersTomer Halevy and Achia UrbachComparing ESC and iPSC-Based Models for Human Genetic DisordersShin Kawamata, Hoshimi Kanemura, Noriko Sakai, Masayo Takahashi and Masahiro J. GoDesign of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell ProductsYoussef Hibaoui and Anis FekiConcise Review: Methods and Cell Types Used to Generate Down Syndrome Induced Pluripotent Stem CellsChapter 10: Immune ResponseMeilyn Hew, Kevin O'Connor, Michael J. Edel, Michaela LucasThe Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases